Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™)
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen acquires a new state-of-the-art Bruker rapifleX™ MALDI mass spectrometer for ultra-fast and high resolution mass spectrometry imaging of its Bead-AMS™ proteomic bead-arrays
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen awarded two US Patents (9,513,285 and 9,523,680) providing broad coverage for its Bead-AMS™ technologies
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen pioneers new Bead Array Mass Spectrometry Technology (Bead-AMS™) and is awarded 3 U.S. patents providing broad coverage
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonPaper published in Nature’s Scientific Reports “Proteome-wide drug screening using mass spectrometric imaging of bead-arrays” describing drug-discovery application of Bead-AMS™ including detection of on- and off-target drug binding
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen receives US Patent 9,334,530 for its Bead-AMS™ technology describing synchronization of mass spectrometric and fluorescence images of mass-tagged bead arrays
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonPaper published in Liver International “Anti-Kelch-like 12 and Anti-Hexokinase 1: Novel Autoantibodies in Primary Biliary Cirrhosis” resulting from a collaboration between AmberGen, INOVA Diagnostics and MGH
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen receives US Patent 8,932,879 for its pioneering PC-PRINT™ technology
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonAmberGen receives US Patent 8,906,700 providing broad coverage on PC-PURE™ technology for biomarker isolation and use in highly sensitive and quantitative assays
/in News, PIONEERING NEW TECHNOLOGIES /by Annmarie ThompsonMenu
Menu 2
Recent News
- AmberGen announces that Dr. Michael Easterling, PhD will join Board of Directors
- AmberGen Announces New Appointments for John Gillespie & Dr. Kenneth J. Rothschild
- AmberGen and Bruker Collaborate on Spatial Biology Imaging Reagents for MALDI-Immunohistochemistry (MALDI-IHC)
- Dr. Mark Lim of AmberGen was honored to be an invited keynote speaker at the “Innovation in Mass Spectrometry Imaging Omics” Session